Skip to main content

Improved Drug Susceptibility Testing (DST) for Mycobacteria

Agency: National Institutes of Health

Assistance Listings
  • 93.855 -- Allergy and Infectious Diseases Research

Forecasted opportunityLast Updated: Jun 24, 2026

Important dates

  • Forecasted post date: March 12, 2027
  • Forecasted application due date: May 28, 2027
  • Forecasted award date: June 1, 2028
  • Forecasted project start date: June 1, 2028
  • Fiscal Year: 2028

Award details

  • Expected project funding: $3,000,000
  • Expected awards: 3

Award min.

Not specified

Award max.

Not specified

  • Funding opportunity number:RFA-AI-28-018
  • Cost sharing or matching requirement:No
  • Funding instrument type:
    • Cooperative agreement
  • Opportunity Category:Discretionary
  • Opportunity Category Explanation:Not specified
  • Category of Funding Activity:
    • Health
  • Category Explanation:Not specified

History

  • Forecast posted date: June 24, 2026
  • Archive date: Not specified
  • Version: 1

View version history on Grants.gov

Summary

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those currently used for treatment of tuberculosis (TB) and clinically important non-tuberculous mycobacterial (NTM) infections, new drugs and drugs in late-stage clinical development. TB is a leading cause of death from an infectious disease worldwide and drug-resistant strains of TB, including those resistant to new drug regimens, are increasing. In the United States, rates of NTM lung disease are rising, especially among women and older adults, while TB cases have surged to their highest level in ten years. Current assays utilize slow, culture-based processes that do not allow for the rapid testing of mycobacterial strains and their drug susceptibility. Improved DSTs are essential for guiding effective treatment, reducing drug-resistant mycobacterial rates, and preventing new transmissions. This program will support the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

Eligibility

Nonprofit

  • Other Native American tribal organizations
  • Nonprofits non-higher education without 501(c)(3)
  • Nonprofits non-higher education with 501(c)(3)

Government

  • City or township governments
  • State governments
  • Federally recognized Native American tribal governments
  • County governments
  • Public and Indian housing authorities
  • Special district governments

Miscellaneous

  • Other

Education

  • Public and state institutions of higher education
  • Independent school districts
  • Private institutions of higher education

Business

  • For-profit organizations other than small businesses
  • Small businesses

Additional information on eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Documents

No documents are currently available.

Agency contact information

Email: NIAIDDST@mail.nih.gov

NIAIDDST@mail.nih.gov

NIAID DST (Division of Microbiology and Infectious Diseases) Please contact via email.

Link to additional information

No additional information is available

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov